Sanofi (SNY)
(Delayed Data from NSDQ)
$49.01 USD
-0.45 (-0.91%)
Updated May 3, 2024 04:00 PM ET
After-Market: $49.00 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNY 49.01 -0.45(-0.91%)
Will SNY be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
Other News for SNY
Pharma R&D productivity seen improving for the first time in years - Deloitte
Regeneron falls after Q1 miss; announces $3B share buybacks
Sanofi’s Frexalimab Shows Promise in MS Trial
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
SNY Crosses Above Key Moving Average Level